Enzeevu Receives FDA Nod for Treating nAMD

69 Views

Emedinexus 11 April 2025

The US Food and Drug Administration (FDA) has approved Enzeevu (aflibercept-abzv) in 2 mg vial kits and pre-filled syringes for intravitreal injection. Enzeevu is indicated for improving and maintaining visual acuity in patients with neovascular age-related macular degeneration (nAMD).

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.